
Jan 6 (Reuters) - Zentalis Pharmaceuticals Inc ZNTL.O:
ZENTALIS PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS KEY MILESTONES AND EXPECTED MOMENTUM IN THE AZENOSERTIB DEVELOPMENT PROGRAM FOR 2026
ZENTALIS PHARMACEUTICALS INC - DENALI PART 2 TOPLINE READOUT EXPECTED BY YEAR END 2026
ZENTALIS PHARMACEUTICALS INC - ASPENOVA PHASE 3 TRIAL INITIATION PLANNED IN 1H 2026
ZENTALIS PHARMACEUTICALS INC - DENALI PART 2A ENROLLMENT COMPLETED; DOSE CONFIRMATION EXPECTED 1H 2026